John Garner

Poly(lactide)-diacrylate from PolySciTech used in patent describing development of advanced assay method

Blog Post created by John Garner on Apr 9, 2019

Stern, 2019 diagnostic nanoparticles patent.jpg

The ability to rapidly and accurately diagnose a disease state in a patient is critical as this guides the subsequent routes of treatment. A recent patent by Selux Diagnostics Inc. describes the use of PLA-diacrylate (AI036) from PolySciTech (www.polyscitech.com) to develop particles for assay applications. This research holds promise for improved assay methodologies across a wide array of applications including diagnostic applications. Read more: Stern, Eric, Aleksandar Vacic, Alec Nathanson Flyer, Benjamin Spears, and Susan Clardy. "Dissociable nanoparticles with inter alia transition-metal complex catalysts." U.S. Patent Application 15/745,361, filed March 28, 2019. https://patents.google.com/patent/US20190091673A1/en

 

“Abstract: Nanoparticles for use in assay methods for detecting analytes in samples, which comprise a signal inducing agent, e.g. a transition-metal catalyst or a chemiluminophore, a chemiluminophore precursor, a soluble absorber, or a soluble absorber precursor. After binding to an analyte, the nanoparticle is dissociated by a chemical or physical trigger, e.g. an organic solvent or ultrasound, to release the signal inducing agent, which releases a detectable signal via a physical or chemical reaction. The nanoparticles comprising a chemiluminophore, a chemiluminophore precursor, a soluble absorber, or a soluble absorber precursor can also effect chemical reactions that serve as signal amplifiers.”

 

-Biotech, Pharma, Cancer, Research (BPCR) is a free, 1-day scientific networking conference hosted by Akina, Inc. on Aug 28, 2019. See more and register to attend at www.bpcrconference.com

Outcomes